Tuesday, September 08, 2026, MARSEILLE - FRANCE
Recording available soon
Rhythm-sponsored promotional satellite symposium at ESPE 2026
Advancing breakthrough therapy with setmelanotide for patients living with rare hypothalamic melanocortin-4 receptor (MC4R) pathway diseases
During this session, Professor Karine Clément (Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, France), Professor Hanneke van Santen (University Medical Center Utrecht, The Netherlands) and PD Dr Metin Cetiner (University Hospital Essen, Germany) discussed:
Prof. Karine Clément
Please login or signup to unlock the videos.Rhythm Pharmaceuticals is leveraging a IQVIA's Healthcare Professional Authentication solution to identify your eligibility to access this video content. If you already have an IQVIA account using it with other healthcare providers, please click 'Login' otherwise click 'Signup'.
Prof. Hanneke van Santen
Please login or signup to unlock the videos.Rhythm Pharmaceuticals is leveraging a IQVIA's Healthcare Professional Authentication solution to identify your eligibility to access this video content. If you already have an IQVIA account using it with other healthcare providers, please click 'Login' otherwise click 'Signup'.
PD Dr Metin Cetiner
Please login or signup to unlock the videos.Rhythm Pharmaceuticals is leveraging a IQVIA's Healthcare Professional Authentication solution to identify your eligibility to access this video content. If you already have an IQVIA account using it with other healthcare providers, please click 'Login' otherwise click 'Signup'.
Prof. Karine Clément
(France)
Prof. Hanneke van Santen
(The Netherlands)
PD Dr Metin Cetiner
(Germany)